We are live on ! Find out more
KPTI icon

Karyopharm Therapeutics
KPTI

71 hedge funds and large institutions have $587M invested in Karyopharm Therapeutics in 2014 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 33 increasing their positions, 15 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

120% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 15

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

10% less call options, than puts

Call options by funds: $1.99M | Put options by funds: $2.21M

9% less funds holding

Funds holding: 78 → 71 (-7)

17% less capital invested

Capital invested by funds: $704M → $587M (-$117M)

32% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 22

Holders
71
Holders Change
-7
Holders Change %
-8.97%
% of All Funds
2.06%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
15
Increased
33
Reduced
15
Closed
22
Calls
$1.99M
Puts
$2.21M
Net Calls
-$216K
Net Calls Change
-$216K

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$24.3M
2
PHS
PFM Health Sciences
California
+$17.4M
3
State Street
State Street
Massachusetts
+$14.9M
4
SAM
Sectoral Asset Management
Quebec, Canada
+$8.27M
5
Franklin Resources
Franklin Resources
California
+$6.66M

Top Sellers

Rank Fund Capital Flow
1
FCMI
Foresite Capital Management I
California
-$11.3M
2
VAM
Visium Asset Management
New York
-$6.98M
3
GPP
Great Point Partners
Connecticut
-$3.49M
4
Citadel Advisors
Citadel Advisors
Florida
-$2.97M
5
PA
Perceptive Advisors
New York
-$2.13M
Name Holding Trade Value Shares
Change 		Change in
Stake
Geode Capital Management
26
Geode Capital Management
Massachusetts
$2.71M +$1.11M +1,962 +61%
TA
27
Teachers Advisors
New York
$2.45M +$214K +380 +9%
BIM
28
BlackRock Investment Management
Delaware
$2.44M +$257K +456 +11%
EAM
29
EverPoint Asset Management
Connecticut
$2.27M -$570K -1,010 -19%
Bank of New York Mellon
30
Bank of New York Mellon
New York
$2.2M +$580K +1,027 +32%
JP Morgan Chase
31
JP Morgan Chase
New York
$1.91M +$46.3K +82 +2%
Morgan Stanley
32
Morgan Stanley
New York
$1.7M +$125K +221 +7%
TCIM
33
TIAA CREF Investment Management
New York
$1.63M -$29.3K -52 -2%
MOACM
34
Mutual of America Capital Management
New York
$1.4M – – –
Point72 Asset Management
35
Point72 Asset Management
Connecticut
$1.38M +$1.18M +2,094 +393%
PAMU
36
Pictet Asset Management (UK)
United Kingdom
$1.23M +$1.32M +2,347 New
Charles Schwab
37
Charles Schwab
California
$1.07M +$252K +446 +28%
EAM
38
Eventide Asset Management
Massachusetts
$1.05M – – –
California State Teachers Retirement System (CalSTRS)
39
California State Teachers Retirement System (CalSTRS)
California
$875K +$91.4K +162 +11%
PIM
40
Partner Investment Management
California
$753K -$126K -224 -13%
AG
41
Aperio Group
California
$714K +$768K +1,361 New
Swiss National Bank
42
Swiss National Bank
Switzerland
$685K +$275K +487 +59%
Bank of America
43
Bank of America
North Carolina
$584K +$29.9K +53 +5%
U
44
UBS
Switzerland
$558K +$600K +1,064 New
NFA
45
Nationwide Fund Advisors
Ohio
$361K +$32.2K +57 +9%
RhumbLine Advisers
46
RhumbLine Advisers
Massachusetts
$358K -$10.2K -18 -3%
MLICM
47
Metropolitan Life Insurance Company (MetLife)
New York
$342K – – –
Goldman Sachs
48
Goldman Sachs
New York
$334K -$35K -62 -9%
AIG
49
American International Group
New York
$283K +$564 +1 +0.2%
UBS AM
50
UBS AM
Illinois
$283K +$305K +540 New
1
2
3 4

KPTI Hedge Fund Activity: Q3 2014 in Review

71 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q3 2014, worth a combined $587M — down 17% from $704M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of KPTI and 15 opened new positions — a net loss of 7 holders — while 15 trimmed existing stakes and 33 added.

The largest buyer was Fidelity Investments, adding an estimated $24.3M. The largest seller was Foresite Capital Management I, cutting an estimated $11.3M.

  • 71 institutional investors held Karyopharm Therapeutics (KPTI) as of Q3 2014, down from 78 in Q2 2014.
  • Funds reported $587M of Karyopharm Therapeutics stock for Q3 2014, down 17% quarter-over-quarter.
  • 15 funds opened new Karyopharm Therapeutics positions in Q3 2014 and 22 closed out, a net change of -7 holders.
  • The largest Karyopharm Therapeutics buyer in Q3 2014 was Fidelity Investments, an estimated $24.3M added.
  • The largest Karyopharm Therapeutics seller in Q3 2014 was Foresite Capital Management I, an estimated $11.3M sold.

Based on aggregated 13F filings for Q3 2014.